These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 12510695)

  • 1. On the road to California.
    DeWitt N
    Nature; 2002 Dec; 420(6916 Suppl):A9. PubMed ID: 12510695
    [No Abstract]   [Full Text] [Related]  

  • 2. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotechnology consortia versus multifirm alliances: paradigm shift at work?
    Persidis A; Persidis A
    Nat Biotechnol; 1996 Dec; 14(13):1657-60. PubMed ID: 9634847
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechnology in the Medicon Valley.
    Frank L
    Nature; 2002 Dec; 420(6916 Suppl):A27, A29, A31 passim. PubMed ID: 12501124
    [No Abstract]   [Full Text] [Related]  

  • 5. Gold in the ivory tower: equity rewards of outlicensing.
    Edwards M; Murray F; Yu R
    Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. California dreaming.
    Nature; 2004 Oct; 431(7010):723. PubMed ID: 15483565
    [No Abstract]   [Full Text] [Related]  

  • 7. Industrial health research in Canada.
    Morin Y
    CMAJ; 2007 Jun; 176(12):1734; author reply 1734. PubMed ID: 17548390
    [No Abstract]   [Full Text] [Related]  

  • 8. Stem cells: science and society.
    Adusumilli PS; Tuorto S; Patel AN
    Natl Med J India; 2006; 19(1):47-8. PubMed ID: 16570690
    [No Abstract]   [Full Text] [Related]  

  • 9. Finnish biotechnology--built on solid foundations.
    Lähteenmäki R
    Nature; 2002 Dec; 420(6916 Suppl):A34-5, A37, A39. PubMed ID: 12501125
    [No Abstract]   [Full Text] [Related]  

  • 10. Stuck in the middle.
    Fuyuno I
    Nature; 2006 Jul; 442(7100):237. PubMed ID: 16855561
    [No Abstract]   [Full Text] [Related]  

  • 11. Supporting the work of lesser geniuses: an argument for removing obstructions to human embryonic stem cell research.
    Hazuka CD
    Univ Miami Law Rev; 2002 Oct; 57(1):157-220. PubMed ID: 15156896
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotechnology. Stem cells lose market luster.
    Vogel G
    Science; 2003 Mar; 299(5614):1830-1. PubMed ID: 12649456
    [No Abstract]   [Full Text] [Related]  

  • 13. Companies balk at California's patent rules for stem cell research.
    Keim B
    Nat Med; 2007 Jan; 13(1):6. PubMed ID: 17206112
    [No Abstract]   [Full Text] [Related]  

  • 14. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 15. Good faith gone bad-gone good again.
    Bialy H
    Nat Biotechnol; 2005 Jan; 23(1):17. PubMed ID: 15637605
    [No Abstract]   [Full Text] [Related]  

  • 16. Take your partner by the hand..
    Smaglik P
    Nature; 2005 Jun; 435(7046):1281. PubMed ID: 15997477
    [No Abstract]   [Full Text] [Related]  

  • 17. Governing stem cell research in California and the USA: towards a social infrastructure.
    Winickoff DE
    Trends Biotechnol; 2006 Sep; 24(9):390-4. PubMed ID: 16843559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good faith gone bad.
    Bialy H
    Nat Biotechnol; 2000 Nov; 18(11):1123. PubMed ID: 11062389
    [No Abstract]   [Full Text] [Related]  

  • 19. Tough cell to investors. Venture capitalists are wary of investing in companies in which risks in the science may not be rewarded by a health revenue stream.
    Moran N
    Sci Am; 2005 Jul; 293(1):A32-4. PubMed ID: 16008299
    [No Abstract]   [Full Text] [Related]  

  • 20. States race to lead stem-cell research.
    Scherer R
    Christ Sci Monitor (East Ed); 2004 Feb; ():1, 10. PubMed ID: 15457613
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.